Within the past 3 years, University Retina has built their program to be one of the largest clinical trial programs in the Midwest for retinal and macular conditions.
We have a full-time team dedicated to our Clinical Trials program and are able to offer our patients the latest innovative drug and medical device therapeutics for treating retinal and macular diseases. If you are interested in learning more or participating in a clinical trial for macular or retinal disease, please contact us using the button below.
Director of Clinical Research Veeral Sheth, MD, FACS
What are Clinical Trials?
Clinical trials are research studies that look into advanced and cutting edge treatments for diseases of the macula or retina that are not offered to the general public. Clinical trials are generally sponsored by governmental agencies such as the National Institute of Health (NIH), pharmaceutical companies, or non-profit institutions. These therapies may not be currently approved by the Food and Drug Administration (FDA), and data from these studies is often used to help obtain FDA approval.
Participation in clinical trials is never mandatory; our patients only participate if they choose to do so. University Retina, its staff, physicians, and patients participate in clinical trials in order to be able to offer our patients with the latest therapies available for macular diseases and retinal diseases.
How can I participate in a Clinical Trial at University Retina?
Patients that are interested in clinical trials should contact us to schedule an appointment at (708) 687-2222. Please set up an appointment to be evaluated if you are interested in participating, and we will determine whether you qualify for one of our active and enrolling clinical trials.
Please note that not everyone who wishes to participate will be eligible to participate in the trial, as the criteria for inclusion in the trial are often very strict. Regardless of whether you are able to participate or not, the University Retina team is committed to helping all of our patients with their retinal care.
Current Studies
Opthea (OPT-302-1004): A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Vanotech (VAN-2201): Chengdu Origen Biotechnology / “”A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration””
Verona (EYP-1901-202): A phase 2, Multicenter, Prospective, Randomized, Single-Masked, Controlled Study of EYP-1901 (Vorolanib) Insert, a Tyrosine Kinase Inhibitor (TKI), Compared to Afibercept in Subjects with Diabetic Macular Edema (DME)
Unity 4 (UBX1325-04): A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema (Aspire)
Perfuse (PER001-202): A Phase 2a Study to Evaluate Safety and Tolerability after Single Administration of Per-001 Intravitreal Implant in Participants with Diabetic Retinopathy.
Atmosphere (RGX-314-2104): A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD(ATMOSPHERE)
Ascent (RGX-314-3101): RGENEXBIO / “A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD”
Isight (ILS-AMD-201): i-Lumen Scientific, Inc. / “Microcurrent stimulation therapy for nonexudative age-related macular degeneration (i-SIGHT): a multicenter, randomized, sham-controlled, feasibility device trial.”
Janssen (81201887MDG2001): A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD50) Comprated to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Past Studies
NEW DAYStudy: A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
Pavilion Study: A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy
Cool-3 Study: Long Term Evaluation of Efficacy of Cooling Anesthesia for Local Anesthesia During Intravitreal Injection
Catalina (NGM621-GA-201): A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Candela: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Canberra: A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy-ORAL THERAPY
Pagoda Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients With Diabetic Macular Edema. Sponsor: Genentech/RocheNorse Two Study: A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration. Sponsor: Outlook TherapeuticsSalutartis: A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age-related Macular Degeneration. Sponsor: Salutaris Medical Devices
Gallego Study: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech/Roche
Altissimo: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study). Sponsor: Graybug Vision
GTSCOPE: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration. Sponsor: Gyroscope Therapeutics
Ionis: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD). Sponsor: Ionis Pharmaceuticals
Kingfisher Study: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema. Sponsor: Novartis
Lucerne Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration. Sponsor: Genentech/Roche
Archway Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Genentech/Roche
Rhine Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema. Sponsor: Genentech/Roche
Panda 1: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration. Sponsor: Chengdu Kanghong
Topaz Study: Phase 3, multicenter, randomized, masked, controlled, parallel group study of suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO vs. IVT anti-VEGF agent used alone. Sponsor: Clearside Biomedical
Cedar Study: A phase 3, multicenter, study of abicipar pegol in patients with neovascular age-related macular degeneration. Sponsor: Allergan
Panorama: A phase 3, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy. Sponsor: Regeneron
Boulevard: A multiple center, multiple dose, randomized, active comparator controlled, double-masked, parallel group, 24-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravtireally in patients with diabetic macular edema. Sponsor: Genentech/Roche
Chroma: A phase 3, multicenter, randomized double-masked sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration. Sponsor: Genentech/Roche
Onyx: A randomized, double-masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration. Sponsor: RegeneronPhase 2, randomized, double-masked, vehicle-controlled, proof of concept study for topically delivered LHA510 as a maintenance therapy in wet AMD. Sponsor: Alcon
Capella: a phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration. Sponsor: Regeneron.
Protocol OPH1006: An 18 month phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer). Sponsor: Ophthotech.
Protocol OPH1005: Phase 2A open label safety study of Fovista (anti-PDGF BB) regimen administered in combination with anti-VEGF therapy to study sub-retinal fibrosis in neovascular AMD. Sponsor: Ophthotech
Protocol OPH1004: A phase 3 safety and efficacy study of Fovista intravitreous administration in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy. Sponsor: Ophthotech
ORBIT study: Phase 4 study of intravtireal Jetrea for vitreomacular adhesion. Sponsor: Thrombogenics
Diabetic Retinopathy Clinical Research Network (DRCR.net): A collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. Protocols R, V, U, and AC. Sponsor: NEI.
Call or Text Us Today to Schedule an Appointment
Learn more about our locations near Chicago, Illinois! Call us today.
"Dr. Rama Jager and his team are world class. You won't find another physician with this level of skill and compassion.""
- Bryan
"Dr. Jager is the most compassionate and capable doctor I've had the pleasure of knowing. My 66 y/o father had floaters in his eye and got an appointment and (painless) laser procedure within the SAME DAY. Dr. Jager took the time to explain what was wrong and gave a clear solution to my dad's problem. The floaters are gone and, more importantly, our family has been given a peace of mind!""
- Ambika
"Dr. Jager and Byun were awesome! They were very professional and actually cared about my health and vision. The Oak Forest location was by far, fairly priced compared to other local retina specialists. The staff were friendly and the open availability for appointments are immediate. I definitely recommend University Retina. You wont regret it!""
- Tabitha
"I had an eye emergency after cataract surgery that needed to be looked at immediately. Dr. George saw me in the Downers Grove office as soon as I could get there. He gave me the treatment I needed for surgery 5 days later. He and his team are professional experts who treat the patient with kindness and respect. I highly recommend him and his team.""
